Clinical Trials on Alzheimer's Disease

Preliminary Program

Boston, November 1-4, 2017

LATE CALL FOR ABSTRACTS
September 1-15, 2017

www.ctad-alzheimer.com
Welcome ................................................................. p. 3
Program ................................................................. p. 4
  - Wednesday, November 1 ................................. p. 4
  - Thursday, November 2 ................................. p. 5
  - Friday, November 3 ....................................... p. 8
  - Saturday, November 4 ................................. p. 10
Registration/Accommodations ............... p. 12
Dear Colleague,

The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.

Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.

At CTAD 2017 several teams will report the results of their preclinical, Phase II and Phase III trials. This sharing of experiences converges towards a same goal: overcoming the hurdles and speed the development of effective treatments in AD.

We look forward to welcoming you to Boston this November!

Scientific Committee

Susan ABUSHAKRA (San Francisco)
Paul AISEN (San Diego)
Kaj BLENNOW (Molndal)
Merce BOADA (Barcelona)
Maria CARRILLO (Chicago)
Mony John DE LEON (New York)
Rachelle DOODY (Basel)
Bruno DUBOIS (Paris)
Howard FELDMAN (San Diego)
Nich FOX (London)
Giovanni B. FRISONI (Brescia, Geneva)
Lutz FROELICH (Mannheim)
Serge GAUTHIER (Montreal)
Ezio GIACOBINI (Geneva)
Michael GRUNDMANN (San Diego)
Harald HAMPEL (Paris)
Takeshi IWATSUBO (Tokyo)
Ara KHACHATURIAN (Washington DC)
Zaven KHACHATURIAN (Washington DC)
Virginia LEE (Philadelphia)
Constantine G. LYKETOS (Baltimore)
José Luis MOLINUEVO (Barcelona)
Jean-Marc ORGOZOZO (Bordeaux)
Ronald PETERSEN (Rochester)
Craig W. RITCHIE (Edinburgh)
Augustin RUIZ (Barcelona)
Robert RISSMAN (San Diego)
Stephen SALLOWAY (Providence)
Philip SCHELTENS (Amsterdam)
Lon SCHNEIDER (Los Angeles)
Eric SIEMERS (Philadelphia)
Peter SNYDER (Rhode Island)
Reisa SPERLING (Boston)
Yaakov STERN (New York)
Jacques TOUCHON (Montpellier)
John TROJANOWSKI (Philadelphia)
Bruno VELLAS (Toulouse)
Michael W. WEINER (San Francisco)
Gordon WINBLAD (Stockholm)

Paul Aisen MD
Alzheimer’s Therapeutic Research Institute (ATRI)
University of Southern California (USC), San Diego, USA

Jacques Touchon MD, PhD
University Hospital of Montpellier
France

Bruno Vellas MD, PhD
University Hospital of Toulouse
France

Mike Weiner MD
University of California
San Francisco (UCSF)
USA
Welcome from the Organizing Committee and Presentation of the CtaD Lifetime Achievement Award to Prof. Bruno Dubois
Jacques Touchon, Paul Aisen, Bruno Vellas, Mike Weiner

Keynote 1
The Evolution of Preclinical Alzheimer’s disease: Implications for Prevention Trials
Reisa Sperling, MD
Professor of Neurology, Harvard Medical School
Director, Center for Alzheimer Research and Treatment
Brigham and Women’s Hospital and Massachusetts General Hospital Memory Disorders Unit Boston, USA

Symposium 1
Importance of Serotonin in Alzheimer’s Disease Psychosis and the Potential Role of Pimavanserin
Moderator: Jeffrey Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

1. Role of 5-HT2a Receptors in the Pharmacology of Alzheimer’s disease Psychosis
Stephen M. Stahl, MD, PhD, Ethan S. Burstein, PhD
(1) University of California, San Diego, CA, USA; (2) ACADIA Pharmaceuticals Inc., San Diego, CA, USA

2. Clinical Trial of Pimavanserin in Alzheimer’s disease Psychosis
Clive Ballard, MBChB, MRCpsych, Carol Banister, MBChB, MRCPsych, Jim Youakim, MD, Bruce Coate, MPH, Srdjan Stankovic, MD, MSPH, on behalf of the ADP Investigators
(1) University of Exeter Medical School, Exeter, UK; (2) King’s College, London, UK; (3) ACADIA Pharmaceuticals Inc., San Diego, CA, USA

3. Review of Pimavanserin Clinical Results in the Context of Historical Alzheimer’s disease Psychosis Trials
Pierre N. Tariot, MD, Randall Owen, MD, Doral Fredericks, PharmD, MBA
(1) Banner Alzheimer’s Institute and University of Arizona College of Medicine, Phoenix, AZ, USA; (2) ACADIA Pharmaceuticals Inc., San Diego, CA, USA
OC1 - A Phase 2a Exploratory Endpoint Trial in Mild-Moderate Alzheimer’s Disease of LM11A-31-BHS p75 neurotrophin receptor ligand.
Frant N. Longo, MD, PhD; Manfred Windisch, PhD; Niels Andreassen, MD; Agneta Nordberg, MD, PhD

OC2 - Tau Accumulation Observed using Repeated Tau PET Measures Predicts Cognitive Decline in Normal Elderly
Bernard Hanseuu2, Beth Mormino1, Alex Becher1, Aaron Schultz1, Jorge Sepulcre1, Kathryn Papp3,4, Heidi Jacobs1, Jasmeer Chhatwal5, Dorene Rentz2,4, Reisa Sperling1,4, and Keith Johnson1,2,4

OC3 - Clinical evaluation of #8F-PI-2620, a next generation TAU PET agent in subject with alzheimer disease and progressive supranuclear PALSY
Andrew Stephens1, John Seiby5, Andre Mueller1, Olivier Barret1, Mathias Berndt1, Jennifer Madonia2, David Alagille2, Hanno Schiererstein1, Heiko Kroth1, Santiago Bullich1, Andrea Pfeifer2, Andreas Muhs3, Gilles Tamagnan4, Kenneth Marell1, Ludger Dinhelborg1

OC4 - Optimizing the Preclinical Alzheimer’s Cognitive Composite (PACC) with Semantic Testing
Kathryn V. Papp PhD1,2, Dorene M. Rentz PsyD1,2, Irina Orlovsky MA1,2, Elizabeth C. Mormino PhD1,2

OC5 - Can IT Help with the Screening for Alzheimer’s Disease Trials? From EHR to Web-Based Cognitive Tests and e-Consent.
Michael W. Weiner, MD1, Peter Schueler, MD1,2, J. Wesson Ashford, MD, PhD1,3, Bruno Vellas, MD, PhD1,2

OC6 - Amyloid Beta Oligomers in Alzheimer’s Disease: a Missing Piece of the Alzheimer’s Puzzle
Jeffrey Cummings MD1, Sandrine Andrieu MD, MPH1, Philip Scheltens MD, PHD1, Kaj Blennow MD, MDH1, Pandel Petr Kocis PhD1, John A. Hey PHD2, A. Power, MD2, Martin Tolar, MD, MDH, PhD1, Susan Abushakra, MD5, Susan Abushakra, MD5, Susan Abushakra, MD5

OC7 - ABBV-8E12, a Humanized Anti-Tau Monoclonal Antibody for the Treatment of Early Alzheimer’s Disease: A 96-Week, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Kumar Budur1, Hana Florian1, Deli Wang1, Weinig Robieson1, Holly Soares1, Joel B. Braunstein2, David M. Holtzman3, Randall J. Bateman1, Beatrice Rendenbach-Mueller1, Nuno Mendonca1, Sandrine Andrieu MD, MPH1,2, Philip Scheltens MD, PHD1, Kaj Blennow MD, MDH1, Pandel Petr Kocis PhD1, John A. Hey PHD2, A. Power, MD2, Martin Tolar, MD, MDH, PhD1, Susan Abushakra, MD5, Susan Abushakra, MD5, Susan Abushakra, MD5

OC8 - Stratification of Pre-Symptomatic and Cognitively Normal Individuals using Polygenic Scoring
Maryam Shoai, PhD1, Richard Pither, PhD2, Valentina Escott-Price, PhD3, Simon M Laws, PhD4, Harald Hampel, MD, PhD, Simone Lista, PhD1, Rik Vandenberge1,2, Isabelle Cleyner1,2, David Irwin, MD1,2, Vivian Van Derlin, MD, PhD1,2, Greg Davidson, PhD1,2, Virginia M.-Y. Lee, PhD1,2, John Q. Trojanowiski, MD, PHD1,2, John Hardy, PhD DSc1,2,3

Coffee Break and Poster Session

OC1 - A Phase 2a Exploratory Endpoint Trial in Mild-Moderate Alzheimer’s Disease of LM11A-31-BHS p75 neurotrophin receptor ligand.
Frant N. Longo, MD, PhD; Manfred Windisch, PhD; Niels Andreassen, MD; Agneta Nordberg, MD, PhD

OC2 - Tau Accumulation Observed using Repeated Tau PET Measures Predicts Cognitive Decline in Normal Elderly
Bernard Hanseuu2, Beth Mormino1, Alex Becher1, Aaron Schultz1, Jorge Sepulcre1, Kathryn Papp3,4, Heidi Jacobs1, Jasmeer Chhatwal5, Dorene Rentz2,4, Reisa Sperling1,4, and Keith Johnson1,2,4

OC3 - Clinical evaluation of #8F-PI-2620, a next generation TAU PET agent in subject with alzheimer disease and progressive supranuclear PALSY
Andrew Stephens1, John Seiby5, Andre Mueller1, Olivier Barret1, Mathias Berndt1, Jennifer Madonia2, David Alagille2, Hanno Schiererstein1, Heiko Kroth1, Santiago Bullich1, Andrea Pfeifer2, Andreas Muhs3, Gilles Tamagnan4, Kenneth Marell1, Ludger Dinhelborg1

OC4 - Optimizing the Preclinical Alzheimer’s Cognitive Composite (PACC) with Semantic Testing
Kathryn V. Papp PhD1,2, Dorene M. Rentz PsyD1,2, Irina Orlovsky MA1,2, Elizabeth C. Mormino PhD1,2

OC5 - Can IT Help with the Screening for Alzheimer’s Disease Trials? From EHR to Web-Based Cognitive Tests and e-Consent.
Michael W. Weiner, MD1, Peter Schueler, MD1,2, J. Wesson Ashford, MD, PhD1,3, Bruno Vellas, MD, PhD1,2

OC6 - Amyloid Beta Oligomers in Alzheimer’s Disease: a Missing Piece of the Alzheimer’s Puzzle
Jeffrey Cummings MD1, Sandrine Andrieu MD, MPH1, Philip Scheltens MD, PHD1, Kaj Blennow MD, MDH1, Pandel Petr Kocis PhD1, John A. Hey PHD2, A. Power, MD2, Martin Tolar, MD, MDH, PhD1, Susan Abushakra, MD5, Susan Abushakra, MD5, Susan Abushakra, MD5

OC7 - ABBV-8E12, a Humanized Anti-Tau Monoclonal Antibody for the Treatment of Early Alzheimer’s Disease: A 96-Week, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Kumar Budur1, Hana Florian1, Deli Wang1, Weinig Robieson1, Holly Soares1, Joel B. Braunstein2, David M. Holtzman3, Randall J. Bateman1, Beatrice Rendenbach-Mueller1, Nuno Mendonca1, Sandrine Andrieu MD, MPH1,2, Philip Scheltens MD, PHD1, Kaj Blennow MD, MDH1, Pandel Petr Kocis PhD1, John A. Hey PHD2, A. Power, MD2, Martin Tolar, MD, MDH, PhD1, Susan Abushakra, MD5, Susan Abushakra, MD5, Susan Abushakra, MD5

OC8 - Stratification of Pre-Symptomatic and Cognitively Normal Individuals using Polygenic Scoring
Maryam Shoai, PhD1, Richard Pither, PhD2, Valentina Escott-Price, PhD3, Simon M Laws, PhD4, Harald Hampel, MD, PhD, Simone Lista, PhD1, Rik Vandenberge1,2, Isabelle Cleyner1,2, David Irwin, MD1,2, Vivian Van Derlin, MD, PhD1,2, Greg Davidson, PhD1,2, Virginia M.-Y. Lee, PhD1,2, John Q. Trojanowiski, MD, PHD1,2, John Hardy, PhD DSc1,2,3
OC9 - Objective Cognitive Decline in Preceding Years Relates to Self-Report on the Cognitive Function Index in the Harvard Aging Brain Study

Rebecca E. Amariglio PhD1,2, Rachel F. Buckley PhD2,4,5, Elizabeth C. Mormino PhD2,3, Dylan R. Kirn MPH2, Gad A. Marshall MD2,3, Keith A. Johnson MD2,3, Dorene M. Rentz PsyD2,3, Reisa A. Sperling MD2,3

1 Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA; 2 Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; 3 Harvard Medical School, Boston, MA, USA; 4 Florey Institutes of Neuroscience and Mental Health, Melbourne, Australia; 5 Melbourne School of Psychological Science, University of Melbourne, Australia

OC10 - The Generation Program : Evaluating CNP520 Efficacy in Preclinical Alzheimer’s Disease

Cristina Lopez Lopez, MD, PhD1, Pierre N. Tariot, MD2, Angelitha Caputo, PhD3, Fonda Liu, Pharm.D4, Marie-Emmanuelle Riviere, PhD5, Marie-Laure Rouzade-Dominguez, PhD6, Ronald G. Thomas, PhD7, Jessica B. Langbaum, PhD7, Rob Lenz, MD, PhD8, Eric M. Reiman, MD, PhD9, Ana Graf, MD9

1 Novartis Pharma, Basel, Switzerland; 2 Banner Alzheimer’s Institute, Phoenix, AZ, USA; 3 University of California-San Diego, San Diego, CA, USA; 4 Amgen, Thousand Oaks, CA, USA.

OC11 - A Phase Ib, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 (abeotaxane) in Patients with Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy; or the Secondary Tauopathy, Alzheimer’s Disease.

Adam Boxer, MD, PhD; Zachary Miller, MD; Richard Tsai, MD, MBA; Mary Koestler, RN, PhD; Julio Rojas, MD, PhD; Peter Ljubimov, MD; Howie Rosen, MD; Gil Rabinovici, MD; Anne Fagan-Niven, PhD; Yann Cobigo, PhD; June Jung, PhD; Phi Luong, BA; Emmeline Chuu, BA; Ryan Powers, BA; Paige Mumford, BA; Bruce Miller, MD; Erik Roberson, MD, PhD

1 Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA; 2 Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA; 3 Department of Neurology, University of Alabama School of Medicine, Birmingham, AL, USA

OC12 - High dose B Vitamin therapy selectively improves cognitive function indicative of cerebrovascular status in the randomized FAVORIT Ancillary Cognitive Trial

Tammy M. Scott1,2, Aron M. Troen1,2, Irwin H. Rosenberg1

1 Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston MA; 2 Friedman School of Nutrition Science and Policy, Tufts University, Boston MA; 3 Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel
Thursday, November 2

**Keynote 2**
*From Academy to Industry: Perspectives for Drug Trials in AD*

Rachelle Doody, MD, PhD
Global Head of Neurodegeneration PD Neuroscience
F. Hoffmann-La Roche, Basel, Switzerland

**Late Breaking Oral Communications**

**Symposium 3**
*EPOCH Trial of the BACE1 Inhibitor Verubecestat for Mild-to-Moderate Alzheimer’s Disease*

Egan, MD1; James Kost, PhD1; Pierre N. Tariot, MD2; Paul S Aisen, MD3; Jeffrey L. Cummings, MD, ScD4; Bruno Vellas, MD, PhD5; Yuhi Muhai, MD6; Tiffini Voss, MD7; Christine Furtelt, MS8; Erin Mahoney, MS9; Rilt Vandenberghe, MD10; Yi Mo, PhD11; David Michelson, MD12

1. Merck & Co., Inc, Kenilworth, NJ, USA; 2. Banner Alzheimer’s Institute, Phoenix, AZ, USA; 3. University of Southern California, San Diego, CA, USA; 4. Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; 5. Gerontopole, INSERM U1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France; 6. University Hospital of Leuven, Leuven, Belgium
Friday, November 3

08:30 – 10:00 a.m.

Oral Communications

**OC15 - Long-Term Cognitive Decline in Patients with Alzheimer’s Disease in Association with Treatment with Cholinesterase inhibitors-data from SveDem, the Swedish Dementia Registry**

Maria Erlandsdotter MD, PhD, Sara Garcia-Pracek MD, PhD, Ingemar Kåreholt PhD, Dorota Religa MD, PhD, Peter Nordström MD, PhD, Anders Wimo MD, PhD, Bengt Winblad MD, PhD.

(i) Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Genetics, Karolinska Institutet, Huddinge, Sweden; (ii) Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden; (iii) Aging Research Center, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institute and Stockholm University, Stockholm, Sweden; (iv) Institute of Gerontology, School of Health and Welfare, Jönköping University, Jönköping, Sweden; (v) Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division for Neurogenetics, Karolinska Institutet, Huddinge, Sweden; (vi) Department of Community Medicine and Rehabilitation, Geriatric Medicine, Umeå University, Umeå, Sweden.

The primary health care of Hudiksvall-Nordanstig, Sweden.

**OC16 - Selection of Amyloid Positive Pre-Symptomatic Subjects using Automatic Analysis of Neuropsychological and MRI Data for Cost-Effective inclusion Procedures in Clinical Trials**

Marion Ansart, MSC, Stéphane Elbelbaum, MD, PhD, Olivier Colliot, PhD, Didier Dormont, PhD, Bruno Dubois, Prof, MD, Harald Hampel, Prof, MD, PhD, for the ADNI, and the INSIGHT study group.

(i) Sorbonne Universités, UPMC Univ Paris 06, Inserm, CNRS, Institut du cerveau et la moelle (ICM) - Hôpital de la Pitié-Salpêtrière, Boulevard de l'hôpital, Paris, France; (ii) Irina Paris, Acrimas project-team, Paris, France; (iii) AP-HP, Hôpital de la Pitié-Salpêtrière, Department of Neurology, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Paris, France; (iv) AP-HP, Hôpital de la Pitié-Salpêtrière, Department of Neuroradiology, Paris, France; (v) AXA Research Fund & UPMC Chair, Paris, France.

**OC17 - Physical Activity and Longitudinal Cognition: Results from the Harvard Aging Brain**

Hannah M. Klein, Dylan R. Kim, MPH, Aaron P. Schultz, PhD, Jennifer S. Rabin, PhD, Rachel Buckley, PhD, Dorene M. Rentz, PsyD, Kathryn V. Papp, PhD, Keith A. Johnson, MD, Reisa A. Sperling, MD, MMSc, Jasmine P. Chhatwal, MD, PhD, MMSc.

(i) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; (ii) Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; (iii) Harvard Medical School, Boston, MA, USA; (iv) Harvard School of Public Health, Boston, MA, USA; (v) Harvard School of Public Health, Boston, MA, USA; (vi) Harvard University, Boston, MA, USA; (vii) National Institute on Aging, National Institutes of Health, National Institutes of Health, Bethesda, MA, USA; (viii) Harvard School of Public Health, Boston, MA, USA; (ix) Massachusetts General Hospital, Boston, MA, USA; (x) Harvard School of Public Health, Boston, MA, USA; (xi) Harvard School of Public Health, Boston, MA, USA.

**OC18 - Validation of Tau PET Imaging in Alzheimer’s Disease and Other Tauopathies**

Nikhil Mattisson, MD, PhD, Michael Scholl MD, PhD, Tomas Ohlsson MD, PhD, Andreas Hahn MD, PhD, Olaf Strandberg MD, PhD, Ruben Smith MD, PhD, Olof Nordberg MD, PhD, Stina Nordberg, MD, PhD, Stina Nordberg, MD, PhD, Anna Nordberg, MD, PhD, Stina Nordberg, MD, PhD, Anna Nordberg, MD, PhD, Stina Nordberg, MD, PhD, Anna Nordberg, MD, PhD.

(i) Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden; (ii) Memory Clinic, Ståde University Hospital, Malmö, Sweden; (iii) Department of Radiation Physics, Ståde University Hospital, Lund, Sweden; (iv) Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria; (v) Department of Clinical Physiology and Nuclear Medicine, Ståde University Hospital, Lund, Sweden; (vi) Department of Neurology, Ståde University Hospital, Lund, Sweden.

**OC19 - TOMMORROW: A Trial to Delay the Onset of MCI Due to AD and Qualify a Unique Genetic Algorithm Biomarker: Study Update**

Kathleen A. Welsh-Bohmer, PhD, Brenda L. Plassman, PhD, Carl Chiang, PhD, Meredith Culp, BS, Patrick Harrigan, BChE, Janet O’Neil, MBA, Ryan Walter, BS, Stephen Haneline, MS, Julian Arbuckle, BSc (Hons), Shyama Brewster, BSc (Hons), Yuha Maruyama, D.V.M., Tom Swanson, BSCE, MBA, Dominic Fitzsimmons, BSc (Hons), Alexandria S. Atkins, PhD, Sarah Rowelev, PhD, Richard Keefe, PhD, Craig Metz, MD, PhD, Karen Bach, MD, PhD, Ann M. Saunders, PhD, Ferenc Martenyi, MD for the TOMMORROW study investigators.

(i) Department of Psychiatry & Neurology, Duke University, Durham NC, USA; (ii) Zinfandel Pharmaceuticals, Inc., Chapel Hill NC, USA; (iii) Takeda Development Center Americas, Inc., Deerfield, IL, USA; (iv) NeuroCog Trials, Durham, NC, USA.

**OC20 - Emerging Plasma-Based Therapies for AD**

Montse Costa PhD, D. Allan Butterfield PhD, Norman Reltin MD, PhD.

(i) Grifols Institute S.A., Parets del Vallès, Spain; (ii) Department of Chemistry, University of Kentucky, Lexington KY, USA; (iii) Reltin Consulting LLC, New Jersey, USA.

10:00 – 10:30 a.m.

Coffee Break and Poster Session

10:30 – 11:00 a.m.

Keynote 3: Genetic Aspects In Clinical Trials

John Hardy, Reta Lila Weston Institute of Neurological Studies, University College London, London, UK

11:00 – 11:30 a.m.

Oral Communications

**OC21 - Cognitive Run-In Periods for Amyloid-Positive Enriched Secondary Prevention Trials.**

Andrew J. Aschenbrenner, PhD, Jason Hassenstab, PhD, Eric McDade, DO, Guoqiao Wang, PhD, Tammie L.S. Benzingter, MD, PhD, Randall J. Bateman, MD, & John C. Morris, MD.

(i) Department of Neurology, Washington University in St. Louis; (ii) Department of Psychological and Brain Sciences, Washington University in St. Louis; (iii) Department of Biostatistics, Washington University in St. Louis; (iv) Department of Radiology, Washington University in St. Louis.
Friday, November 3

OC22 - Eigen Combinations of Cognition and Biomarkers to Minimize the Sample Sizes in Prevention Trials on Alzheimer’s Disease
Chenqi Li1,2, PhD, Anne M. Fagan2,3, PhD, Tammie Benzinger1,5, PhD, Jason Hassenstab2,3, PhD, John C. Morris2,3, MD, Randall J. Bateman3,6, MD.
(1) Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA; (2) Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; (3) Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; (4) Department of Mathematics, Washington University School of Medicine, St. Louis, MO, USA; (5) Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA; (6) The Dominantly Inherited Alzheimer Network, Washington University School of Medicine, St. Louis, MO, USA

OC23 - The Alzheimer’s Prevention Registry and GeneMatch: Accelerating Recruitment and Enrollment into Alzheimer’s Studies
Jessica B. Langbaum, PhD, Nellie High,1 David Gordon1, Jodie Nichols1, Trisha Walsh1, Eric M. Reiman1, MD, Pierre N. Tariot1, MD
(1) Banner Alzheimer’s Institute, Phoenix, AZ, USA

OC24 - An Examination of Rate of Decline as an Alternative to Change from Baseline
Howard Mackey, PhD1, Nan Hu, PhD2, Michael Ahmadi, MSC2, Yinxue Chen, MSc1, Pierre Tariot, MD1, Eric M Reiman, MD1, Francisco Lopera, MD1, Kewei Chen, PhD2, Ronald Thomas, PhD2
(1) Genentech, Inc., South San Francisco, CA, USA; (2) Banner Alzheimer’s Institute, Phoenix, AZ, USA; (3) Universidad de Antioquia, Medellín, Colombia; (4) UC San Diego Department of Neurosciences, CA, USA

OC25 - The Safety and Efficacy of Edonerpic (T-817) in Patients with Mild to moderate Alzheimer’s Disease
Lon S. Schneider, MD1, Ronald G. Thomas, PhD2, James Brewer, MD,2 Suzanne Hendrix, PhD3, Robert Rissman, PhD4, David Salmon, PhD1, Hiroshi Kobayashi, Howard Feldman, MD1, for the ADCT TCAD group
(1) Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; (2) University of California, San Diego, CA, USA; (3) University of California, San Diego, CA, USA; (4) Pentara Corporation, San Diego, CA, USA; (5) Toyama Chemical, Ltd, Tokyo, Japan

OC26 - Safety of and Tolerability of Gantenerumab in the Open-Label Extension of SCarlet RoAD Trial, a Global Study in Patients with Prodromal Disease
Mirjana Andjelkovic, PhD1, Danielle Abi-Saab, PsyD1, Nathalie Pross, PhD1, Paul Delmar, PhD1, Nicola Voyle, PhD1, Michaela Mertes1,2,3,4,6, PhD
(1) Hoffman LaRoche, Basel, Switzerland; (2) Roche Products Limited, Welwyn, UK

Lunch and Poster Session

OC27 - The European Prevention of Alzheimer’s Dementia (EPAD) and Amyloid Imaging for Prevention of Alzheimer’s Dementia (AMYPAD) Projects: Cohort Readiness for the Adaptive Clinical Trial Platform.
Andrew Satlin, MD1, Craig Ritchie MD PhD2, Mija Kvivekto MD PhD2, Alina Soloman MD PhD2, Brian Tom PhD2, Jose Luis Malinuevo MD PhD3, Scott Berry PhD4, Frederik Barthof MD PhD3, Gill Farr PhD5
(1) Eisai Pharmaceuticals, USA (2) Centre for Dementia Prevention, University of Edinburgh, UK (3) Ageing Research Centre, Karolinska Institute, Sweden (4) MRC Biostatistics Unit, University of Cambridge, UK (5) Barcelona Beta Brain Research Centre, Spain (6) Berry Consultants Ltd, Texas, USA (7) VU University Medical Centre, Amsterdam, The Netherlands (8) General Electric, Amersham, UK

OC28 - Towards a New Biomarker of Drug Development in Alzheimer’s Disease
Olivier Blin, MD, PhD1, Régis Bordet MD PhD4, Jill Richardson PhD1, Pierre Payoux MD PhD1, Claudio Babiloni MD PhD1, David Barreto-Faz MD PhD2, Catherine Cassé-Perot PhD1, Giovanni Frisoni MO PhD2
(1) University of Aix-Marseille (2) University of Lille (3) GSK (4) University of Toulouse (5) University of Roma (6) University of Barcelona (7) University of Geneva

Coffee Break and Poster Session

Keynote 4
Rationale, Design and Progress of the 3 Active Alzheimer’s Prevention Initiative Trials
Pierre Tariot, MD, Banner Alzheimer’s Institute, University of Arizona College of Medicine, Phoenix, AZ - USA

Syposium 4
Results from the Phase 3 MINDSET STUDY: A Global, Double-Blind, Placebo-Controlled Study of Intepridene in Mild-to-Moderate Alzheimer’s Disease
• Presentation 1: Analysis of primary efficacy and safety results
• Presentation 2: Analysis of secondary endpoints and measures of clinical meaningfulness
• Discussion and Q&A
Saturday, November 4

08:30 – 10:00 a.m. Oral Communications

**OC29 - ORY-2001 Rationale in Mild to moderate Alzheimer’s Disease**
Roger Bullock, MD1, Cesar Molinero MD,PhD2, Tamara Maes PhD1
1) Oxigen Genomics S.A. Barcelona Spain

**OC30 - Plasma Amyloid Levels within the Alzheimer’s Process and Correlations with Central Biomarkers**
Olivier Hanon, MD, PhD1, Jean-Sébastien Vidal MD, PhD2, Sylvain Lehmann MD, PhD2, Stéphanie Bombois MD, PhD2, Bernadette Allingnant MD1, Marie Godin Msc1, Patrick Gelé MD2, Christine Delmaire MD1, Frederic Boillot MD1, PhD1, S Schraen MD3, Audrey Gabelle MD, PhD1 and the BALTAZAR study group.
1) Department of Geriatrics, Branco Hospital, Paris, France ; 2) Laboratoire de Protéomique Clinique, Department of Biochemistry, Saint Eloi Hospital, IRM, Inserm U1083, France ; (3) CRMR de Lille, Department of Neurology, Lille, France ; (4) Centre de Psychiatrie et Neurosciences, Université Paris Descartes, Paris, France ; (5) University of Lille Nord de France, Department of Biology and Pathology, Lille University Hospital, INSERM UMR 172, 59037 Lille, France ; (6) CRMR de Strasbourg, Department of Gerontology, Strasbourg, France ; (7) CRMR de Montpellier, Department of Neurology, Inserm U1083, Montpellier, France.

10:00 – 10:30 a.m.

10:30 – 11:30 a.m. Late Breaking Oral Communications

11:30 – 12:30 p.m.

Symposium 5
Sympatic and Network Dysfunction in Alzheimer’s Disease (AD): Translational Insights and Therapeutic Opportunities

Moderator: Arjen Brussard, PhD, Amsterdam Neuroscience, VU Medical Center, Amsterdam, Netherlands

1. Targeting unfolded protein response and synaptic dysfunction to enhance memory function and prevent neurodegeneration
Giovanna Mallucci, MD PhD2,3
1) Dept. of Clinical Neurosciences, University of Cambridge, Cambridge, UK ; (2) UK Dementia Research Institute at University of Cambridge, Cambridge, UK ; (3) MRC Toxicology Unit, Leicester, UK

2. Modulation of synaptic and network activity and endocytosis with light flicker therapy reduces amyloid pathology in mouse model of AD
Li-Hueh Tsai, PhD1
1) Picower Institute of Memory and Learning, Massachusetts Institute of Technology, Cambridge MA, USA

3. Preclinical rationale and early clinical results of p38 alpha kinase inhibition to reverse hippocampal synaptic dysfunction
John Alam, MD1
1) EIP Pharma, LLC, Cambridge MA, USA
Lunch and Poster Presentation

Clinical Trials Prescreening Focus Panel: Prescreening Initiatives to Identify Individuals with Preclinical or Early Alzheimer’s Disease for Clinical Trials

Moderator: Jamie A. Mullen, MD, AstraZeneca, Waltham MA, USA

1. The Funnel study: Prescreening for MCI and mild AD patients from the CHARIOT Register
   Neuroepidemiology and Ageing Research Unit, School of Public Health, Imperial College London, UK

2. A prescreening study using amyloid PET to improve recruitment for early Alzheimer’s disease drug trials
   Christopher C. Rowe, MD, Austin Health, Melbourne, Australia

3. Models of Patient Engagement in Alzheimer’s Disease (MOPEAD): a European project to move Alzheimer’s disease environment towards an earlier diagnosis
   Mercé Boada, MD, PhD1; Laura Campo2; Dhaenal Desai3; Hans Peter Hundemer1; Octavio Rodriguez-Gomez, MD1
   Bengt Winblad, Prof, MD, PhD1; Frankt Jessen, MD, PhD1; Peter Jelle Visser, MD, PhD1; Milica Kramberger, MD, PhD1
   Rafael Simo, MD, PhD1; Rafael Navajo4; Annette Dumas1; Jean Georges, BA4; David Krivec2; Peggy Maguire4
   Dereck MacKenzie1
   (1) Fundación ACE. Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain; (2) Eli Lilly and Company Ltd, Basingstoke, United Kingdom; (3) AstraZeneca AB, Södertälje, Sweden; (4) Lilly Deutschland GmbH, Bad Homburg, Germany; (5) Karolinska Institutet, Center for Alzheimer Research, Div. of Neuropsychiatrics, Huddinge, Sweden; (6) German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany; (7) Stichting VUmc, Amsterdam, Netherlands; (8) University Medical Centre Ljubljana, Ljubljana, Slovenia; (9) Institut de Recerca Hospital Universitari Vall d’Hebron (IRVH), Barcelona, Spain; (10) GMV Soluciones Globales Internet S.A.U., Barcelona, Spain; (11) ASM Consulting, Auderghem, Belgium; (12) Alzheimer Europe, Luxembourg, Luxembourg; (13) Spomincica – Alzheimer Slovenia, Ljubljana, Slovenia; (14) European Institute of Women’s Health, Dublin, Ireland; (15) KITE Innovation (Europe) Ltd, Huddersfield, United Kingdom

2:15 – 3:15 p.m.

Oral Communications

   Jason Hassenstab, PhD2,3,4, Andrew J. Aschenbrenner, PhD5,6, Martin J. Siwiwinski, PhD7, Eric McDade, DO,8, Yen Ying Lim, PhD9, Paul Maruff, PhD10, David A. Balota, PhD10,11, John C. Morris, MD12,13, Randall J. Bateman, MD14, & The Dominantly Inherited Alzheimer Network-Trials Unit.
   (1) Department of Neurology, Washington University School of Medicine, St. Louis, MO USA; (2) Department of Psychological & Brain Sciences, Washington University in St. Louis, St. Louis, MO USA; (3) The Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), Washington University School of Medicine, St. Louis, MO USA; (4) Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO USA; (5) Department of Human Development and Family Studies, Pennsylvania State University, Stone College, PA USA; (6) The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia; (7) Cogstate Ltd, Melbourne, Victoria, Australia

OC36 - Associating Cognitive Functioning Profiles with Amyloid Status in ADNI2, with Implications for Adaptive Screening for Amyloid
   Sarah J Carr PhD1, Judith Jaeger PhD2, Nancy Maserejian ScD1, Ahmed Enayatallah3, Alan Lerner3,4, Yannming Wang6, Sheng Yang3, Wenting Wang4, Shijia Bian6, Curtis Tatsuoka PhD6 and for the Alzheimer’s Disease Neuroimaging Initiative*
   (1) Department of Neurology, Case Western Reserve University, Cleveland, OH, USA; (2) CognitionMetrics, DE USA; (3) Department of Psychosocial and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY, USA; (4) Biogen, Cambridge, MA, USA; (5) Neurological Institute, University Hospitals Case Medical Center, Beachwood, OH USA; (6) Department of Radiology, Case Western Reserve University, Cleveland, OH USA; (7) Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH USA

OC37 - Alzheimer’s Disease Dementia and the Long-Term Impact on Caregiver Burden – 36-Month results from GERAS
   Catherine Reed, PhD1, Mark Belger, BSc1, J. Scott Andrews, PharmD1, Antje Tochthom-Heidenreich, MSc1
   (1) Eli Lilly and Company Limited, Windlesham, UK; (2) Eli Lilly and Company, Indianapolis, IN, USA

OC38 - Neuroprotective Effect of a New Photobiomodulation Technique against Amyloid Aβ25-35 Peptide-Induced Toxicity in Mice.
   Guillaume J. Blevet, MS1, Johann Meunier, PhD2, Francois J. Roman, PhD3, Jacques Touchon, MD, PhD4,5
   (1) REGEN-LIFE SAS, Montpellier, France; (2) Amylegen SAS, Montferrier-sur-Lozé, France; (3) INSERM U1061, Montpellier, France; (4) University of Montpellier, France

3:15 – 4:15 p.m.

Late Breaking Oral Communications

4:15 – 4:30 p.m.

Closing Session

CTAD 2017
**REGISTRATION**

**Early bird fees (until September 1)**

1. Regular Registration (no lunches) **€895** - Regular registration (with 3 lunches) **€1024**
2. EADC Member registration (no lunches) **€704** - Regular registration (with 3 lunches) **€833**
   (to benefit from this rate you must be an active member of the European Disease Consortium)

**Full registration fees (After September 2)**

1. Regular Registration (no lunches) **€1027** - Regular registration (with 3 lunches) **€1156**
2. EADC Member registration (no lunches) **€854** - EADC Member registration (with 3 lunches) **€983**
   (to benefit from this rate you must be an active member of the European Disease Consortium)

Please note that registration to CTAD 2017 includes:
- access to all conference sessions, attendee bag, one-year online subscription to the Journal of Prevention of Alzheimer’s Disease (JPAD) and CTAD abstracts

You can register directly on our website www.ctad-alzheimer.com

**ACCOMMODATIONS**

**Book your accommodation at the Conference Venue**

This year again CTAD has negotiated a special price to stay at the Boston Park Plaza where CTAD will be held.

**Boston Park Plaza**
50 Park Plaza at Arlington Street
Boston, MA 02116-3912

- The price for a single room is **$279** (including breakfast)
- The price for a double room is **$319** (including breakfast for 2 people)

Make sure your book your room early on to ensure you stay at the conference venue.

**Book your room on our website www.ctad-alzheimer.com**
CTAD Alzheimer

Get in touch

CTAD BOSTON 2017
CTAD Congress
Phone: +33 4 67 10 92 23
Email: ctad@ant-congres.com
www.ctad-alzheimer.com

Follow us on

@CTAD2017   CTAD Alzheimer   CTAD Conference

#CTAD2017

www.ctad-alzheimer.com